Hindustan Biosciences Limited is engaged in the manufacturing and sale of pharmaceutical products.Product Portfolio: a) Tablets b) Capsules c) Eye/Ear/Nasal Drops d) Dry and Liquid Injectables e) Liquid/Dry Syrups f) Pre-Filled Syringes g) Non Sterile/Sterile Ointments
Hindustan Bio Sciences will hold its 34th Annual General Meeting on September 30 at its registered office. The company has informed shareholders about the AGM, e-voting procedures, and book closure. E-voting will be available from September 27 to September 29. Shareholders eligible to vote will be determined as of September...
Hindustan Biosciences has announced the publication of its financial results for the quarter ended June 30, 2026. The company reported zero revenue from operations and incurred total expenses of 0.11 Cr, leading to a net loss of 0.11 Cr for the period. The Board of Directors approved these unaudited results,...
Hindustan Biosciences Limited confirmed that its Registrar and Share Transfer Agent did not receive any requests for dematerialization or rematerialization of equity shares during the quarter ending June 30, 2026. This means no physical share certificates were submitted by investors to be converted into electronic form, and no electronic shares...
Hindustan Bio Sciences Limited has published its audited financial results for the latest quarter and full financial year. These important financial updates are now accessible on the company’s website and also on the BSE Limited website. This release provides essential financial transparency for shareholders and fulfills crucial disclosure requirements, allowing...
Hindustan Biosciences' Board approved the audited financial results for the fourth quarter and the financial year ended March. The company reported a total revenue of 0.74 Cr and a loss of 0.08 Cr for the financial year. Total assets stood at 3.20 Cr, with share capital at 2.05 Cr. The...
